

# Drug Policy

<b>Policy:</b>	<b>ADHD Non-Stimulant Products Step Therapy</b>	<b>Annual Review Date:</b> <b>03/21/2024</b>
<b>Impacted Drugs:</b>	<b>Kapvay (clonidine hydrochloride ER)</b> <b>Strattera (atomoxetine)</b>	<b>Last Revised Date:</b> <b>03/21/2024</b>

## OVERVIEW

There are four non-stimulant medications approved for the treatment of attention deficit/hyperactivity disorder (ADD/ADHD): atomoxetine (Strattera, generics), guanfacine extended-release tablets (Intuniv, generics), and clonidine extended-release tablets (Kapvay, generics). Atomoxetine is a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD in children  $\geq 6$  years of age, adolescents and adults. Guanfacine extended-release tablets and clonidine extended-release tablets, both of which are alpha agonists, are approved for use in children and adolescents aged 6 to 17 years with ADHD. Guanfacine extended-release tablets and clonidine extended-release tablets are indicated for use as monotherapy, or as adjunctive therapy to stimulant medications.

## POLICY STATEMENT

A preferred step therapy program has been developed to encourage the use of a preferred product prior to the use of a non-preferred product. If the preferred step therapy rule is not met for a non-preferred agent at the point of service, coverage will be determined by the preferred step therapy criteria below. All approvals are provided for 1 year in duration.

**Automation:** Patients with a history of one Preferred product within the 130-day lookback period are excluded from step therapy.

### Preferred Medications

- Generic clonidine hydrochloride ER
- Generic guanfacine ER
- Generic atomoxetine

### Non-Preferred Medications

- Kapvay
- Strattera

## PREFERRED STEP THERAPY CRITERIA

1. If the patient has tried a preferred medication, then authorization for a non-preferred medication may be granted.

# Drug Policy

## Initial Approval/ Extended Approval.

A) *Initial Approval:* 1 year

B) *Extended Approval:* 1 year

---

## Step Therapy Exception Criteria

Approve for 1 year if the patient meets the following (A, B, or C):

- A. The patient has an atypical diagnosis and/or unique patient characteristics which prevent use of all preferred agents. If so, please list diagnosis and/or patient characteristics **[documentation required]**; **OR**
- B. The patient has a contraindication to all preferred agents. If so, please list the contraindications to each preferred agent **[documentation required]**; **OR**
- C. The patient is continuing therapy with the requested non-preferred agent after being stable for at least 90 days [verification in prescription claims history required] or, if not available, [verification by prescribing physician required] AND meets ONE of the following:
  - 1. The patient has at least 130 days of prescription claims history on file and claims history supports that the patient has received the requested non-preferred agent for 90 days within a 130-day look-back period AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product); **OR**
  - 2. When 130 days of the patient's prescription claims history file is unavailable for verification, the prescriber must verify that the patient has been receiving the requested non-preferred agent for 90 days AND that the patient has been receiving the requested non-preferred agent via paid claims (i.e. the patient has NOT been receiving samples or coupons or other types of waivers in order to obtain access to the requested non-preferred agent) AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product).

**Documentation Required:** When documentation is required, the prescriber must provide written documentation supporting the trials of these other agents, noted in the criteria as **[documentation required]**. Documentation should include chart notes, prescription claims records, and/or prescription receipts.

**Approval Duration:** All approvals for continuation of therapy are provided for 1 year unless noted otherwise below. In cases where the initial approval is authorized in months, 1 month is equal to 30 days.

---

## Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or

---

# Drug Policy

performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

## REFERENCES

1. Strattera® capsules [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2017.
2. Kapvay® extended-release tablets, oral [prescribing information]. Atlanta, GA: Shionogi Pharma, Inc.; August 2016.
3. Nash K, Carter KJ. Treatment options for the management of pervasive developmental disorders. *Int J Psychiatry Med.* 2016;51(2):201-210.
4. Treuer T, Gau SS-F, Mendez L, et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. *J Child Adolesc Psychopharmacol.* 2013;23(3):179-193.
5. Clemow DB, Mason OW, Sarkis EH, et al. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. *Expert Rev Neurother.* 2015;15(11):1353-1366.
6. Howes OD, Rogdaki M, Findon JL, et al. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. *J Psychopharmacol.* 2018;32(1):3-29.
7. Guanfacine hydrochloride. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 8 March 2024. Accessed on 19 March 2024.
8. Clonidine hydrochloride. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 6 March 2024. Accessed on 19 March 2024.
9. Atomoxetine hydrochloride. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 6 March 2024. Accessed on 19 March 2024.
10. Atomoxetine. In: Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc.; Riverwoods, IL. Available at: <http://www.online.lexi.com>. Last updated 6 March 2024. Accessed 19 March 2024.
11. Clonidine. In: Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc.; Riverwoods, IL. Available at: <http://www.online.lexi.com>. Last updated 19 March 2024. Accessed 19 March 2024.
12. Guanfacine. In: Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc.; Riverwoods, IL. Available at: <http://www.online.lexi.com>. Last updated 19 March 2024. Accessed 19 March 2024.